News | April 14, 2026
Roche wins CE mark for blood-based MS brain damage test
The new test offers a minimally invasive blood-based approach to tracking neurological damage, measuring neurofilament light chain
The new test offers a minimally invasive blood-based approach to tracking neurological damage, measuring neurofilament light chain
The partnership aims to fuse antibody-drug conjugation (ADC) technology with targeted protein degradation
The solution integrates key molecular cloning methods—including Golden Gate, Gibson assembly, and restriction/ligation—alongside primer design, Sanger sequencing analysis, and protein translation in a single application
The data will be presented at the 2026 European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Munich, April 17-21
They also differentiated the innovator biologic Semaglutide molecule from newer synthetic or chemical generic versions entering the market
DBT-BIRAC, BioE3 and the Rs 10,000-crore Biopharma SHAKTI scheme aim to accelerate innovation, biomanufacturing and exports
Government outlines advanced shared infrastructure and DBT-ICGEB biofoundry expansion to fast-track lab-to-market innovation across six strategic biotech sectors
Eylea 2mg (intravitreal aflibercept injection) is an anti-VEGF therapy that blocks a protein responsible for abnormal blood vessel growth and leakage in the retina
The company has achieved a turnover of around Rs 100 crore in FY 2025–26 and aims to achieve a turnover of Rs 500 crore in next three years
Broadens downstream purification portfolio with next-generation Protein A chromatography for scalable manufacturing
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
